SOUTHLAKE, Texas--(BUSINESS WIRE)--OncoNano Medicine, Inc., a biotechnology company developing ultra pH-sensitive micelles for the detection, staging and treatment of cancer, today announced two poster presentations – including a late-breaking abstract – for the Society for the Immunotherapy of Cancer (SITC) Annual Meeting to be held in National Harbor, Maryland, November 6-10. OncoNano’s core technology is a library of tunable, ultra pH-sensitive micelles that exist intact under baseline physiological pH conditions but dissociate to release their payload under different, predesignated pH levels.
“We are very pleased to share data for two of our lead products at the SITC Annual Meeting this year,” commented Ravi Srinivasan, CEO of OncoNano Medicine. “Our proprietary micelle technology is designed to enable us to deliver high-value and challenging payloads to target tissues with high specificity in ways that have not been possible before.”
The first poster, which is a late-breaking abstract, will feature ONM-500 [Mi-Vax™] – an injectable micelle composed of STING (Stimulator of Interferon Genes)-activating polymers and packaged with a human papilloma virus tumor specific antigen. These micelles are subcutaneously injected where they accumulate in the lymph nodes and are endocytosed by dendritic cells. The lower pH of intracellular endosomes causes micelle dissociation, releasing both the antigen and STING-activating polymer to coordinate a targeted attack on cancer cells. OncoNano was awarded a grant from the Cancer Prevention and Research Institute of Texas (CPRIT) to continue the advancement of ONM-500 through pre-clinical and clinical development.
The second poster features ONM-400 [ON-BOARD™], OncoNano’s injectable pH-sensitive therapeutic delivery platform that exploits a universal feature of cancer, the relatively acidic tumor microenvironment. ONM-400 can be loaded or conjugated with a variety of cancer therapeutics including cytokines, small molecules and engineered antibody fragments to focus therapeutic delivery specifically at the site of the tumor, minimizing off-target delivery to potentially improve the efficacy and safety profile. OncoNano plans to continue advancing the ONM-400 program through preclinical development and toward the clinical stage where there is substantial unmet need for more effective strategies to target cancer.
Late-breaking Poster Presentation
Abstract title: ONM-500 - A Novel STING-Activating Therapeutic Nanovaccine Platform for Cancer Immunotherapy
Presenting Author: Jason B. Miller, Ph.D., OncoNano Medicine, Inc.
Poster Number: P857
Date: November 8, 2019, 12:30-2:00 PM and 6:30-8:00 PM
Poster Presentation
Abstract title: Delivery of Interleukin-2 to the Acidic Tumor Microenvironment by Ultra-pH Sensitive Nanoparticles for Immunotherapy
Presenting Author: Xinliang Ding, Ph.D., OncoNano Medicine, Inc.
Poster Number: P617
Date: November 8, 2019, 12:30-2:00 PM and 6:30-8:00 PM
About OncoNano Medicine
OncoNano Medicine is developing a new class of pH-activated compounds that digitalize and exploit the variability of pH in disease. pH variability is a proven, simple, and effective identifier of diseased tissue providing a foundation for the development of a broad range of highly targeted therapeutics and imaging agents. OncoNano is the first company to advance product candidates using pH as a biomarker for cancer immunotherapy, therapeutic use and intraoperative imaging based on its pH-sensitive micelle technology. www.OncoNanoMed.com
